Ask Warren

JONBUR Research · Initiation

You're reading an earlier report from Oct 18, 2026. See the latest report

Huons · 243070 · Biotech & Pharma

Huons: Shares Down 40.6% in a Year as Profit Margins Narrow and Merger Filings Continue

Why this report

Start of coverage: written when a reader opened this company and there was no report yet.

Huons closed at ₩18,050 on 2026-10-16, near its 52-week low of ₩17,250 and 40.6% lower than a year earlier. Trailing operating margin has fallen to 3.6% from 7.3% in 2025, while filings show a merger decision and a disclosure-related designation.

Written Oct 18, 2026 · Data as of Oct 16, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a picture of a steady revenue base with weakening profitability. Trailing twelve-month revenue is ₩607.8B, slightly below 2025's ₩620.8B, while operating income is ₩22.0B versus ₩45.6B for 2025. The share price has fallen 10.4% in one month and 31.0% in three months, and the market is pricing the company at 0.6 times book value.

On the other side, the balance sheet looks manageable, free cash flow is positive at ₩33.4B, and the dividend yield is 5.1%. The model estimate sits far above the share price, but it rests on assumptions that earnings recover, which the latest trailing numbers do not yet show. The data does not give details on the merger terms, so its effect on value cannot be judged here.

Business overview

Huons is a KOSDAQ-listed company in the Biotech & Pharma sector, founded on 2016-05-03 and listed on 2016-06-03. CEO is Song Soo-young. It has 11,979,665 listed shares and a market capitalisation of about ₩216.2B.

Revenue has grown every year in the data, from ₩436.9B in 2021 to ₩620.8B in 2025. Growth slowed from 12.7% in 2022 and 12.1% in 2023 to 6.9% in 2024 and 5.2% in 2025. A news item dated 2026-10-18 from Money Today mentions Huons Lab expanding application of 'HyDiffuse' under a subcutaneous formulation change; no financial detail is provided.

Every earlier JONBUR Research report and update note on Huons, with Pro.

Unlock with Pro

Model estimate of fair value

Bear
₩45,072
+165%
Base
₩76,573
+350%
Bull
₩129,034
+658%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 25, 2026Update noteModel fair value changeHuons: Model Fair Value Estimate Cut to ₩51,504 Base Case as Discount Rate Edges Lower and Bear Case Falls Sharply
  2. Oct 18, 2026InitiationStart of coverage (reader request)Huons: Shares Down 40.6% in a Year as Profit Margins Narrow and Merger Filings Continue

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information